Perilesional Injection Research Articles

Interferon γ treatment for cervical intraepithelial neoplasia

Eight patients with cervical intraepithelial neoplasia (CIN) were administered perilesional injections of human recombinant interferon γ (IFN-γ), and the response was evaluated by colposcopy and exfoliative cytology and then by histopathology. In all patients, colposcopic and cytologic findings improved after two to four injections of IFN-γ and the cytologic findings reverted to normal in five of these eight patients. All five were free of dysplastic lesions. The other three patients with positive cytology and positive colposcopy after completion of IFN-γ treatment underwent hysterectomy or laser conization, and histopathologic examination revealed residual dysplastic lesions. On the other hand, a control study revealed that only one of eight patients showed spontaneous regression during the 3-month observation period. During the course of these treatments, keratinizing cells were often present in the cervical smears and isolated cell keratinization was often evident in the residual dysplastic lesions of the surgical specimens. These observations suggest that IFN-γ treatment is an effective therapeutic method for CIN lesions and that IFN-γ has the potential to differentiate nonkeratinizing squamous cells into keratinizing cells.

Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma

We assessed the feasibility of using lymphokine-activated killer cells (adoptive immunotherapy) with infusions of interleukin-2 when given regionally in three patients with unresectable primary hepatocellular carcinoma (PHC). In 2 patients, 2 cycles, which included a bolus of LAK (10 7 to 10 8 cells followed by a 4-hourly infusion of IL-2 were administered via selective arterial catheterization of the hepatic artery. One further patient received 3 cycles of IL-2 alone by direct intralesional and perilesional injections. Minimal toxicity was observed and side effects such as fever were comparable to those observed with systemic infusions of IL-2 alone. Serial α-fetoprotein (AFP) levels initially fell but subsequently rose within 2 to 4 weeks of therapy. AFP levels had not reached pre-treatment values at 4 months in 2 patients, 1 of whom was alive and well at 15 months follow-up.

Preoperative cutaneous lymphoscintigraphy in malignant melanoma.

To identify the regional lymph node basins cutaneous lymphoscintigraphy with technetium 99m rhenium sulfide colloid (99mTc-ReS) was performed in 45 patients and with technetium 99m antimony sulfide colloid (99mTc-Sb2S3) in seven patients after excisional biopsy of the primary tumor. All patients had skin tumors located in the face or neck or on the trunk with 47 cases of cutaneous malignant melanoma and 5 cases of benign or premalignant lesions. In 48 patients the scintiscans 1 hour after perilesional injection of the tracer colloid clearly showed the lymphatic drainage patterns from the tumor sites, of them 25 patients demonstrated unidirectional drainage, whereas the remaining 23 patients had multidirectional drainage to two or three lymph node groups. There were technical difficulties in performing the examinations in four patients. The authors recommend cutaneous lymphoscintigraphy as a safe, simple and reliable technique for mapping the lymphatic drainage preoperatively in patients with Stage I cutaneous malignant melanoma of axial localization.

Treatment of keloids by single intraoperative perilesional injection of repository steroid

Treatment of keloids by single intraoperative perilesional injection of repository steroid

Treatment of keloids by single intraoperative perilesional injection of repository steroid.

Keloid management remains controversial, and recurrence and untoward side effects limit the use of many techniques. During a seven-year period, I surgically treated 19 children, aged 3 to 17 (mean 10.5 years), with a total of 28 keloids. After aseptic skin preparation, the interface between the keloid and normal skin or subcutaneous tissue was injected with betamethasone sodium phosphate and betamethasone acetate suspension (Celestone Soluspan). The lesion was excised, and the defect was closed with subcutaneous polyglycolic acid suture. No further therapy was given. There has been no dermal or subcutaneous atrophy, and there have been no recurrences after an average follow-up of 35.5 months (six months to nine years). The technique is simple and successful, and avoids the painful postoperative series of injections often advocated.

Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon‐gamma

Successful immunotherapy of early s.c. or i.p. (B16) melanoma in syngeneic C57BL/6 (B6) mice was achieved with s.c. peri-lesional injections (for s.c. tumors) or i.p. injections (for i.p. tumors) of recombinant human interleukin 2 (rIL-2) and recombinant murine interferon-gamma (rIFN-gamma). Over a 28-day period, rIL-2 and rIFN-gamma were injected 14 times. Results with this combination were additive with s.c. tumors and synergistic with i.p. tumors. Treatment with 6,250 U-25,000 U of rIL-2 and 2 micrograms of rIFN-gamma began 1-3 days after s.c. inoculation of melanoma. On day 50, 87% (72/83) of mice thus treated were completely free of tumor. None of the 78 control mice (tumor + buffer) survived. Of mice receiving either rIL-2 or rIFN-gamma alone, 59% (47/79) and 53% (44/83), respectively, were tumor-free. I.p. tumors were also eradicated by i.p. injections of rIL-2 (50,000 U) with rIFN-gamma (5, 10, and 15 micrograms) as judged by absence of tumor in 81% (21/26) of mice autopsied between days 45 and 65. No control mice survived, and only 17% (2/12) and 20% (6/30) given either rIL-2 or rIFN-gamma separately (i.p.) were tumor-free. Doses of rIFN-gamma from 1-4 micrograms were more beneficial in eliminating 1-day s.c. melanomas than were higher doses, and local s.c. treatment was far superior to distant or systemic treatment. Non-adherent peritoneal or splenic cells from mice bearing 6-day-old i.p. melanomas and treated with one or both lymphokines on days 3 and 4 were used in cytotoxicity assays in vitro. Significant cytotoxicity against cultured melanoma cells was displayed by cells harvested from lymphokine-treated mice, but there was no evidence of the synergism observed with combination treatment of i.p. tumors in vivo. rIFN-gamma inhibited proliferation of melanoma cells in vitro, whereas rIL-2 stimulated proliferation at 1,000 U/ml. Plating efficiency was increased by at least 30% by culture with 100 U or 1,000 U of rIL-2/ml and both concentrations neutralized the inhibitory effect of 0.05 ng/ml of IFN-gamma, but not of 0.5 or 5.0 ng/ml.

Cervical intraepithelial neoplasia treated by perilesional injection of interferon : Choo YC; Seto WH; Hsu C; et al. Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, Hong Kong Br. J. Obstet. Gynaecol.; 93/4 (372–379) 1986

International Journal of Gynecology & ObstetricsVolume 25, Issue 2 p. 170-170 Citations from the literature oncology Cervical intraepithelial neoplasia treated by perilesional injection of interferon Choo YC; Seto WH; Hsu C; et al. Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, Hong Kong Br. J. Obstet. Gynaecol.; 93/4 (372–379) 1986 First published: April 1987 https://doi.org/10.1016/0020-7292(87)90019-1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume25, Issue2April 1987Pages 170-170 RelatedInformation

Cervical intraepithelial neoplasia treated by perilesional injection of interferon : Choo YC; Seto WH; Hsu C; et al. Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, Hong Kong BR. J. OBSTET. GYNAECOL.; 93/4 (372–379) 1986

International Journal of Gynecology & ObstetricsVolume 24, Issue 6 p. 476-476 Citations from the literature oncology Cervical intraepithelial neoplasia treated by perilesional injection of interferon Choo YC; Seto WH; Hsu C; et al. Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, Hong Kong BR. J. OBSTET. GYNAECOL.; 93/4 (372–379) 1986 First published: December 1986 https://doi.org/10.1016/0020-7292(86)90049-4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume24, Issue6December 1986Pages 476-476 RelatedInformation